Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Avalyn Pharma (NASDAQ:AVLN) to a hold rating in a report issued on Wednesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley began coverage on Avalyn Pharma in a report on Tuesday. They set an “overweight” rating and a $53.00 price target on the stock. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $52.00 price objective on the stock. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price objective on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Finally, Guggenheim began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $80.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $59.00.

Avalyn Pharma Trading Up 5.9%

Shares of NASDAQ AVLN opened at $28.39 on Wednesday. Avalyn Pharma has a 1-year low of $25.05 and a 1-year high of $32.22.

Insiders Place Their Bets

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 34.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jill Carroll bought 277,778 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 14.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.